FDA Approves First Adjuvant Therapy for Most Common Type of Lung Cancer
WASHINGTON, D.C. — The U.S. Food and Drug Administration has approved Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have a specific …
Read More